Stock Screener App

Gratuito -

0.2249

12.68% +0.0253

Pre-mercato: .235 0.0101 +4.49%

Cns Pharmaceuticals Inc (CNSP)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione Frazionamento azionario

Cns Pharmaceuticals Inc Borsa (CNSP) Ultime notizie

CNS Pharmaceuticals Reports First Quarter 2024 Financial Results - Yahoo Canada Finance

Yahoo Canada Finance

CNS Specific Antisense Oligonucleotides Market 2023 Trends with Analysis on Key Players Akcea Therapeutics, Inc ... - Amoré

CNSP: Riding the Market Waves of Growth and Decline in 2023 – Invest Chronicle - The InvestChronicle

The InvestChronicle

Investing in Cns Pharmaceuticals Inc (CNSP): What You Must Know – Knox Daily - Knox Daily

Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing ... - Yahoo Finance

CNS Pharmaceuticals to Present at the LSX World Congress 2024 - Yahoo Finance

Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK ... - Yahoo Finance

CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical ... - Yahoo Finance

Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day - Business Wire

Xenon Pharmaceuticals Engages at Stifel CNS Event - TipRanks.com - TipRanks

Avadel Told To Pay Jazz Pharma $234K Over Narcolepsy Drug IP - Law360

CNS Pharmaceuticals Strives to Regain Nasdaq Compliance - TipRanks.com - TipRanks

Gene and Cell Therapies Targeting CNS Disorders Market is Predicted to Exhibit Remarkable Growth by 2032 ... - GlobeNewswire

Top 5 Health Care Stocks That Are Preparing To Pump In February

Top 5 Health Care Stocks That Are Preparing To Pump In February - CNS Pharma (NASDAQ:CNSP), Biolase (NASD - Benzinga

Why UPS Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Why Super Micro Computer Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering - Yahoo Finance

Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors - Yahoo Finance

Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc ... - Yahoo Finance

CNS Startup Myrobalan Therapeutics Raises $24M Series A - Law360

Elite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant - Yahoo Finance

CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of ... - Yahoo Finance

Global CNS Therapeutics Strategic Report 2023: Market to Reach $199 Billion by 2030 - Developing Market to Drive ... - Yahoo Finance

AiBtl signs $667m licensing deal for ABVC’s CNS drug - Pharmaceutical Technology

Pharmaceutical Technology

ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ... - GlobeNewswire

Cognito Therapeutics Appoints Greg Weaver as Chief Financial Officer - Business Wire

SK Biopharm eyes Asia's No.1 spot in radioactive drug market - Korea Economic Daily

Korea Economic Daily

Busting the Brain's Firewall: How Lantern Pharma's Algorithms Can Predict a Drug's Ability to Reach the Brain - dallasinnovates.com

dallasinnovates.com

JOANN And 3 Other Stocks Under $4 Insiders Are Aggressively Buying - Avalo Therapeutics (NASDAQ:AVTX), CNS ... - Benzinga

CNS Pharmaceuticals enrols over 100 subjects for GBM trial - Clinical Trials Arena

Clinical Trials Arena

EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company ... - GlobeNewswire

Lucy Therapeutics Appoints Neuroscience Drug Discovery and Development Expert Christopher J. Winrow, Ph.D., as ... - Business Wire

Federal Circuit Affirms Jazz Pharmaceutical's Risk Evaluation and Mitigation Strategy Patent Is Not Listable in Orange ... - Wilson Sonsini

CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the ... - PR Newswire

Lantern Pharma Announces Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central ... - Business Wire

Jazz Pharma ruling clears U.S. roadblock for rival narcolepsy drug - Reuters

CNS Pharmaceuticals Announces Investigator-Initiated Phase 1b/2 Trial to be Conducted at the Pomeranian Medical ... - PR Newswire

Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer - PR Newswire

CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch Event - PR Newswire

CNS Pharmaceuticals Appoints Faith L. Charles, JD as Chair of the Board of Directors - PR Newswire

CNS Pharmaceuticals Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for ... - PR Newswire

SciNeuro Pharmaceuticals Announces the Appointment of Guojun Bu, Ph.D., as Chief Scientific Officer, and Provides ... - PR Newswire

CNS Pharmaceuticals Announces Reverse Stock Split - PR Newswire

Glioblastoma Multiforme Treatment Market Size to Hit $10.2 BN By 2030 - BioSpace

CNS doses first subject in brain cancer treatment trial in France - Clinical Trials Arena

Clinical Trials Arena

CNS Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update - BioSpace

Glioma Pipeline Insights | Clinical Trial Research Evaluation Report By DelveInsight - PR Newswire

CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global ... - PR Newswire

CNS to commence study of Berubicin for glioblastoma multiforme - Clinical Trials Arena

Clinical Trials Arena

$76.97

4.27%

$151.22

2.59%

$29.65

1.89%

$171.03

3.73%

$376.60

0.10%

$92.98

0.85%

Apri su Yahoo | Apri su Google | Aperto in Finviz